Provides laboratory testing services through BioReference Laboratories. Develops and commercializes pharmaceutical products, including Rayaldee. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
An average decline of 24% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit indicators sit around the sector average.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Growth: Sales growth trails the sector average.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
An investor who bought at the very peak is down 70% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 12 months, company executives reported 52 buys and 1 sell. Management buying with its own money is usually read as a good sign.
A loss of $225.7M against $606.9M in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts about 1.6 years. After that, the company needs to find new money.
On our five-subject report card, OPK sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: OPK’s sales are going backwards, and it closed last year at a loss. The road back runs through both.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.